文献速递消化系统肿瘤

FOLFIRINOX联合氯沙坦全程新辅助治疗后放化疗治疗局部晚期胰腺癌:一项2期临床试验

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项单臂2期试验在49例局部晚期不可切除胰腺癌患者中评估FOLFIRINOX联合氯沙坦后放化疗的R0切除率。结果显示R0切除率为69%(95%CI 55%-82%),中位无进展生存期17.5个月,中位总生存期31.4个月。结论认为该全程新辅助治疗可使肿瘤降期,R0切除率为61%。

要点

  • 49例局部晚期不可切除胰腺癌患者接受FOLFIRINOX联合氯沙坦8周期后放化疗,R0切除率达69%。
  • 42例(86%)尝试手术,34例(69%;95%CI 55%-82%)实现R0切除。
  • 总体中位无进展生存期17.5个月,中位总生存期31.4个月。

核心结论

  • FOLFIRINOX联合氯沙坦及放化疗的全程新辅助治疗可使局部晚期胰腺导管腺癌降期,R0切除率为61%。

研究设计与样本

  • 单臂2期临床试验,于2013年8月22日至2018年5月22日在一家大型学术医院开展。
  • 纳入49例经多学科评估为既往未治疗的局部晚期不可切除胰腺癌患者,ECOG体力状态评分0或1,血液、肾脏和肝脏功能充足。
  • 研究完成时27例仍存活患者的中位随访时间为17.1个月(范围5.0-53.7个月)。

主要发现

  • 49例患者(26例女性,23例男性;中位年龄63岁,范围42-78岁)中,39例完成8周期FOLFIRINOX联合氯沙坦;10例未完成8周期,原因包括疾病进展(5例)、氯沙坦不耐受(3例)和毒性(2例)。
  • 7例(16%)接受短程放化疗,38例(84%)接受长程放化疗。
  • 42例(86%)尝试手术,34例(69%;95%CI 55%-82%)实现R0切除。
  • 总体中位无进展生存期为17.5个月(95%CI 13.9-22.7),中位总生存期为31.4个月(95%CI 18.1-38.5)。
  • 在接受切除的患者中,中位无进展生存期为21.3个月(95%CI 16.6-28.2),中位总生存期为33.0个月(95%CI 31.4至未达到)。

关键数值与推荐

  • 患者接受FOLFIRINOX联合氯沙坦治疗8周期。
  • 化疗后影像学可切除的患者接受短程放化疗(质子5 GyE×5)联合卡培他滨。
  • 持续血管受累的患者接受长程放化疗(50.4 Gy,血管加量至58.8 Gy)联合氟尿嘧啶或卡培他滨。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. OBJECTIVE: To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and losartan followed by chemoradiotherapy for locally advanced pancreatic cancer. DESIGN, SETTING, AND PARTICIPANTS: A single-arm phase 2 clinical trial was conducted at a large academic hospital from August 22, 2013, to May 22, 2018, among 49 patients with previously untreated locally advanced unresectable pancreatic cancer as determined by multidisciplinary review. Patients had Eastern Cooperative Oncology Group performance status 0 or 1 and adequate hematologic, renal, and hepatic function. Median follow-up for the analysis was 17.1 months (range, 5.0-53.7) among 27 patients still alive at study completion. INTERVENTIONS: Patients received FOLFIRINOX and losartan for 8 cycles. Patients with radiographically resectable tumor after chemotherapy received short-course chemoradiotherapy (5 GyE × 5 with protons) with capecitabine. Patients with persistent vascular involvement received long-course chemoradiotherapy (50.4 Gy with a vascular boost to 58.8 Gy) with fluorouracil or capecitabine. MAIN OUTCOMES AND MEASURES: R0 resection rate. RESULTS: Of the 49 patients (26 women and 23 men; median age 63 years [range, 42-78 years]), 39 completed 8 cycles of FOLFIRINOX and losartan; 10 patients had fewer than 8 cycles due to progression (5 patients), losartan intolerance (3 patients), and toxicity (2 patients). Seven patients (16%) had short-course chemoradiotherapy while 38 (84%) had long-course chemoradiotherapy. Forty-two (86%) patients underwent attempted surgery, with R0 resection achieved in 34 of 49 patients (69%; 95% CI, 55%-82%). Overall median progression-free survival was 17.5 months (95% CI: 13.9-22.7) and median overall survival was 31.4 months (95% CI, 18.1-38.5). Among patients who underwent resection, median progression-free survival was 21.3 months (95% CI, 16.6-28.2), and median overall survival was 33.0 months (95% CI, 31.4 to not reached). CONCLUSIONS AND RELEVANCE: Total neoadjuvant therapy with FOLFIRINOX, losartan, and chemoradiotherapy provides downstaging of locally advanced pancreatic ductal adenocarcinoma and is associated with an R0 resection rate of 61%. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01821729.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019. PMID: 31145418. doi:10.1001/jamaoncol.2019.0892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。